Retention of Enrollees Following a Cancer Diagnosis Within Health Maintenance Organizations in the Cancer Research Network
|
|
- Warren French
- 5 years ago
- Views:
Transcription
1 Retention of Enrollees Following a Cancer Diagnosis Within Health Maintenance Organizations in the Cancer Research Network Terry S. Field, Jackie Cernieux, Diana Buist, Ann Geiger, Lois Lamerato, Gene Hart, Don Bachman, Rick Krajenta, Sarah Greene, Mark C. Hornbrook, Gary Ansell, Lisa Herrinton, George Reed Population laboratories with complete clinical information on episodes of care are needed to support research on the quality of care delivered to cancer patients. Data resources within the Cancer Research Network (CRN) may overcome many of the limitations of existing cancer databases, but their potential clinical value depends on the stability of the enrolled population. To assess this issue, we studied the retention rates among survivors of the patients diagnosed with cancer from January 1, 1993, through December 31, 1998, who were enrolled at five health maintenance organization sites participating in the CRN. Enrollees were followed from cancer diagnosis through death, disenrollment, or the end of follow-up (i.e., December 31, 1999). The retention rate among survivors for all cancers combined at 1 and 5 years after cancer diagnosis was 96.0% (95% confidence interval [CI] 95.9% to 96.1%) and 83.9% (95% CI 83.4% to 84.3%), respectively. The proportion of enrollees diagnosed with cancer who remained enrolled and available for evaluation suggests that the CRN is well-suited for studies of the quality of care for cancer patients, survivorship, and longterm outcomes. [J Natl Cancer Inst 2004;96:148 52] Studies suggest that scientific breakthroughs in cancer treatment are not fully realized in the day-to-day delivery of care (1). To obtain a better understanding of factors related to the quality of cancer care, researchers require access to population laboratories (2) that have substantial numbers of cancer patients, information about all episodes of care in the full range of clinical settings, and adequate follow-up to identify longterm outcomes. However, none of the existing databases of cancer patients in the United States includes these three components (2). In 1998, the National Cancer Institute (NCI) funded a consortium of 10 research groups, based within not-forprofit health maintenance organizations (HMOs), to conduct collaborative research in cancer prevention and control. This consortium, called the Cancer Research Network (CRN), now includes the research programs, enrollee populations, and databases of 11 members of the HMO research network. The CRN HMOs provide care for nearly 9 million enrollees, who represent a large and ethnically diverse population living across the United States. These HMOs provide a continuum of cancer care, from screening through diagnosis and treatment. Treatment provided to patients outside the HMOs is captured in electronic administrative claims at each site. In addition, most of these HMOs also maintain electronic files on pharmacy use, and all have access to electronic medical records or paper charts for inpatient and outpatient care. Hence, the available information allows researchers to take into account patients comorbidities, health status, age, and prior health care use. This array of information resources supports research efforts into the factors associated with optimal cancer care, the long-term impact of cancer treatments, and the cost of cancer care. One potential issue in regard to the value of the CRN as a population laboratory is the stability of the enrolled population. The 11 HMOs that make up the CRN have overall estimated 1-year enrollee retention rates ranging from 84% to 90% and estimated 5-year retention rates ranging from 59% to 76%. However, despite the good overall retention rates for these HMOs, retention rates specifically for enrollees diagnosed with cancer have not been estimated. To address this issue, we conducted a study to determine 1) the percentage of cancer survivors who remained continuously enrolled at 1, 2, 3, 4, and 5 years after cancer diagnosis and 2) the characteristics of enrollees with higher rates of disenrollment during the initial treatment period (defined as the first year following diagnosis). The five CRN sites participating in this study Henry Ford Health System (based in Detroit, MI), Group Health Cooperative (based in Seattle, WA), and Kaiser Permanente in three regions (Northwest [Oregon and Washington State], Northern California, and Southern California) were predominantly staff-model HMOs that had complete cancer registries linked to patient enrollment histories. Together, these five HMOs provided care to more than enrollees in These five CRN sites were a convenience sample in that they were selected because of the interest of local investigators in participating in this study. The estimated 1-year retention rates of the total enrolled populations at these five sites were similar to and matched the range of retention rates across all sites in the CRN, and we have no reason to believe that the retention rates among the cancer patients in these five sites would not be representative of the overall enrolled CRN population. This study was approved by the institutional review board of the University of Massachusetts Medical School (Worcester, MA) and the respective institutional review boards of the participating CRN sites. Study participants were health-plan members who were diagnosed with incident cancer while they were enrolled in one of the five participating HMO sites from January 1, 1993, through December 31, Inclusion of par- Affiliations of authors: Meyers Primary Care Institute, Fallon Healthcare System (TSF, JC) and the University of Massachusetts Medical School (TSF, JC, GR), Worcester, MA; Center for Health Studies, Group Health Cooperative, Seattle, WA (DB, GH, SG); Department of Research and Evaluation, Southern California Permanente Medical Group, Pasadena, CA (AG); Henry Ford Health System, Detroit, MI (LL, RK); Center for Health Research, Kaiser Permanente Northwest, Portland, OR (DB, MCH, GA); Division of Research, Kaiser Permanente Northern California, Oakland, CA (LH). Correspondence to: Terry S. Field, DSc, Meyers Primary Care Institute, 630 Plantation St., Worcester, MA ( terry.field@meyersprimary.org and terry.field@umassmed.edu). See Notes following References. DOI: /jnci/djh010 Journal of the National Cancer Institute, Vol. 96, No. 2, Oxford University Press 2004, all rights reserved. 148 BRIEF COMMUNICATIONS Journal of the National Cancer Institute, Vol. 96, No. 2, January 21, 2004
2 ticipants into the study was based on the first cancer diagnosis for each enrollee during the study time period that was not described as noninvasive, diagnosed at autopsy, or nonmelanoma skin cancer. Cancer registries define the date of cancer diagnosis as the earliest date that the potential patient was brought to the attention of a health care provider. Therefore, these dates could be earlier than the patient was considered enrolled in the HMO, even though the final confirmation of cancer diagnosis and initial course of treatment were carried out by the HMO. Patients whose cancer diagnosis was within 60 days before the start of enrollment were included in this study to ensure that we did not lose these patients. Patients whose cancer diagnosis was within 45 days following termination of enrollment were also included to ensure capture of patients who disenrolled immediately after their cancer diagnosis. Information on enrollees diagnosed with cancer was drawn from electronic data files at each of the participating CRN sites. Each site has a cancer registry that covers the total enrolled population and contains data elements, such as primary cancer site, morphology, general stage, and behavior, that are consistent with the Surveillance, Epidemiology, and End Results (SEER) Program 1 registries. From these cancer registries, data were collected for all eligible cancer diagnoses, including the date of the diagnosis, cancer stage, primary tumor site, morphology and behavior of the tumor, enrollee s age at the time of cancer diagnosis, sex, race and ethnicity, and date of death. Enrollees identified in the cancer registry data were linked to enrollment files from which a complete enrollment history was extracted, including dates of enrollment and disenrollment and type of insurance for each enrollment period until the end of follow-up (i.e., December 31, 1999). At the time of data extraction, all cancer registry and enrollment data at each site were up-to-date through Rates of successful linkages between cancer registry data and enrollment files across the five sites ranged from 96.3% to 100%. The cancer registries at these five sites used a variety of methods to track deaths among those patients who remained enrolled in their HMO and those who disenrolled. Four sites maintained ongoing linkages with the SEER programs in their catchment areas for follow-up, and the fifth site used automated linkages to state death records and search firms to track deaths. Three sites enhanced their SEER linkages for tracking deaths by performing independent searches of state and national death indices. The 5-year follow-up rates for deaths among those patients no longer enrolled in their HMO ranged from 95.0% to 99.8%. Disenrollment date was defined as the first termination (of coverage) date after cancer diagnosis. Patients were considered continuously enrolled in an HMO until the termination date or until the end of follow-up. Data from the cancer registries and enrollment files were used to assess patient characteristics associated with disenrollment during the first year after cancer diagnosis. Sex was categorized as female or male, with the male category including 16 patients coded as other in the registry data. Race and ethnicity were combined, and patients were categorized as Hispanic if they were identified as having a Spanish surname or origin in the cancer registries databases (3). The categories from the cancer registries race variable were retained for those patients not identified as Hispanic. American Indian patients were combined with patients coded under the unknown race category because there were too few patients identified as American Indian to enable us to individually assess their disenrollment. Cancer type was established by combining the cancer registries primary tumor site and morphology variables. For prognosis, we estimated the 5-year survival rates of patients for specific cancer types on the basis of the 5-year survival rates from SEER ( ; see seer.cancer.gov/csr/1975_2000/results _merged/topic_survival.pdf) and categorized these rates in approximate quartiles by their frequency in our sample. For cancer stage, we used the cancer registries SEER general summary stage variable (see gov/tools/ssm/intro.pdf). Enrollment variables included type of insurance and length of continuous enrollment before cancer diagnosis. We categorized insurance type as Medicare, commercial, self-pay, and Medicaid at the time of cancer diagnosis. Because there were only a few patients eligible for both Medicare and Medicaid and their disenrollment rates matched those for patients with Medicaid alone, we combined these two insurance type categories. Patients whose insurance was obtained through a state s expanded Medicaid program were classified as Medicaid. Length of continuous enrollment before cancer diagnosis was categorized, a priori, as less than 30 days, days, 180 days to less than 1 year, 1 to less than 4 years, 4 to less than 10 years, and more than 10 years. After characterizing the population in terms of demographics (e.g., age, sex, and race), cancer types and stages, insurance types, and length of enrollment before cancer diagnosis, we calculated the number of cancer patients who were alive at 1, 2, 3, 4, and 5 years after diagnosis, censoring patients who died without disenrolling and those who had not died or disenrolled by the end of the follow-up period. The number of patients who could be followed differed for each of these calculations according to the year of their diagnosis and the remaining time available before the end of the follow-up period (i.e., December 31, 1999). For example, the only patients who could be followed for 5 years after their cancer diagnosis were those diagnosed in 1993 and We calculated the percentage of eligible survivors who remained continuously enrolled at 1, 2, 3, 4, and 5 years after diagnosis. We repeated this series of calculations for patients within each of the four most frequently occurring cancer types (i.e., breast, prostate, colorectal, and lung/ bronchus) and within each CRN site individually. We also analyzed patient characteristics associated with disenrollment for reasons other than death during the first year after cancer diagnosis to identify any subgroups of patients with high rates of disenrollment. HMO disenrollment among children (i.e., those aged 0 19 years) is primarily based on their parents access to health insurance, so that analyses of disenrollment would have to be run separately in this age group. Moreover, the number of children with cancer in our study was too small for multivariate analysis, so this aspect of our analysis focused only on adults (i.e., those aged 20 years or older). This series of analyses began with calculations of the rates of disenrollment during the first year after cancer diagnosis for each category of the demographic, cancer type and stage, du- Journal of the National Cancer Institute, Vol. 96, No. 2, January 21, 2004 BRIEF COMMUNICATIONS 149
3 Table 1. Characteristics of patients enrolled in five health maintenance organization sites participating in the Cancer Research Network diagnosed with cancer from January 1, 1993, through December 31, 1998 Characteristics patients (%) Race White (76.0) African American (10.3) Asian or Pacific-Islander 7214 (5.4) Hispanic 9714 (7.3) Other/unknown 1191 (0.9) Sex Female (49.2) Male/other* (50.8) Age at first diagnosis during the time period, y (0.3) (0.8) (9.8) (14.6) (23.6) (29.7) (17.6) (3.6) Cancer type Breast (17.7) Prostate (17.2) Lung/bronchus (12.3) Colorectal (10.6) Melanoma, skin 6219 (4.7) Non-Hodgkin s lymphoma 5147 (3.9) Uterine 4123 (3.1) Oral/pharynx 3441 (2.6) Leukemia 3424 (2.6) Bladder 2986 (2.3) Kidney/renal 2839 (2.1) Ovarian 2788 (2.1) Pancreatic 2680 (2.0) Other (16.8) *Includes 16 patients with sex coded as other in the health maintenance organizations electronic cancer registry files. Includes all other cancer types that occurred in less than 2% of our sample. ration of prior enrollment, and insurance type variables. Multivariate models using Cox proportional hazards models were then developed using Stata Statistical Software, release 6.0 (4) to determine the independent association of enrollee characteristics with disenrollment during the first year after cancer diagnosis. Patients whose insurance type was not given in the electronic enrollment files were not included in the analysis using the multivariate models (n 6807). The assumptions of the Cox proportional hazards models were met through review of the Schoenfeld residuals (5) for each covariate and through graphical assessment of the Cox proportional hazards functions (6). We included all of the proposed variables in each multivariate model and controlled for CRN site and year of diagnosis. We assessed all possible two-way interaction terms among variables and found none to be statistically significant. Characteristics of the patients who were diagnosed with cancer during the study period are shown in Table 1. This patient population was 24% nonwhite and had a substantial number of patients in each adult age category (i.e., patients aged 20 years or older). Cancer types with the highest frequency were breast (17.7%), prostate (17.2%), lung/bronchus (12.3%), and colorectal (10.6%). Retention rates among 1-year survivors were 95% or higher for all cancers combined and for breast, prostate, colorectal, and lung/bronchus cancers when assessed individually (Table 2). Oneyear retention rates among survivors varied from 93.0% to 97.0% across the five CRN sites, with a 1-year retention rate among survivors for all cancers combined of 96.0% (95% confidence interval [CI] 95.9% to 96.1%). Fiveyear retention rates among survivors across the five CRN sites were 77% or higher for all cancers combined and for breast, prostate, colorectal, and lung/ bronchus cancers when assessed individually, with a 5-year retention rate among survivors for all cancers combined of 83.9% (95% CI 83.4% to 84.3%; Table 2). Patients with the highest rates of disenrollment during the initial treatment period were aged years, were nonwhite, and had a short length of enrollment before their cancer diagnosis (Table 3). Patients insured through Medicaid had the highest disenrollment rate, with an adjusted hazard ratio for disenrolling of 3.5 (95% CI 2.9 to 4.3). Among the patients who died during the initial treatment period, 98.9% remained enrolled until death (data not shown). Retention rates among survivors diagnosed with all cancers combined were high: 96.0% (95% CI 95.9% to 96.1%) among 1-year survivors and 83.9% (95% CI 83.4% to 84.3%) among 5-year survivors. The proportion of patients who remained enrolled and available for complete assessment of the initial treatment period was sufficient for most studies of the quality and cost Table 2. Cancer survivors continuously enrolled in five health maintenance organization sites participating in the Cancer Research Network 1 5 years after cancer diagnosis* Diagnosis years patients with cancer years of follow-up after diagnosis survivors % of survivors still enrolled (95% CI) Range in % of survivors still enrolled across the five sites All cancers combined (95.9 to 96.1) (92.4 to 92.8) (89.4 to 89.9) (86.6 to 87.3) (83.4 to 84.3) Breast cancer (96.8 to 97.3) (93.5 to 94.2) (91.2 to 92.2) (88.7 to 90.0) (85.6 to 87.4) Prostate cancer (96.5 to 97.0) (93.8 to 94.5) (91.5 to 92.4) (89.0 to 90.2) (86.2 to 87.9) Colorectal cancer (96.6 to 97.2) (93.4 to 94.4) (90.7 to 92.1) (88.4 to 90.4) (85.3 to 88.0) Lung/bronchus cancer (94.4 to 95.5) (90.1 to 92.1) (85.9 to 88.9) (81.9 to 86.0) (77.7 to 83.5) *CI confidence interval. 150 BRIEF COMMUNICATIONS Journal of the National Cancer Institute, Vol. 96, No. 2, January 21, 2004
4 Table 3. Disenrollment among adult enrollees with known insurance type during the first year after cancer diagnosis* Variable patients with cancer of patient care during this time period. Because breast and prostate cancer patients have high rates of 5-year survival, they are of particular interest for studies of long-term outcomes. Retention rates among 5-year survivors of these cancers were more than 86%, suggesting that the CRN is also an appropriate base for survivorship research. Our analyses of subgroups of cancer patients with low retention rates during the first year of treatment identified several groups of patients whose initial treatment might be difficult to follow. The highest rates of disenrollment were among individuals aged years, those insured through Medicaid, and those who were recently enrolled. The CRN s information resources may not directly capture the cancer experience of these groups of patients, but they can % of patients who disenrolled Adjusted hazard ratio (95% CI) Total Age, y (1.7 to 2.1) (1.0 to 1.4) (referent) Sex Female (0.92 to 1.0) Male/other (referent) Race Asian (1.1 to 1.5) African American (1.1 to 1.3) Hispanic (0.95 to 1.2) Other/unknown (1.4 to 2.3) White (referent) Stage of cancer at diagnosis Unstaged/unknown (1.3 to 1.7) Distant (0.98 to 1.2) Regional (0.77 to 0.91) Local (referent) Prognosis Quartile (1.4 to 1.8) Quartile (0.99 to 1.2) Quartile (1.1 to 1.3) Quartile (referent) Enrollment prior to diagnosis 30 days (4.1 to 6.1) days (4.2 to 5.3) days (3.6 to 4.7) 1to 4 years (2.7 to 3.2) 4to 10 years (1.5 to 1.9) 10 years (referent) Type of insurance Medicaid (2.9 to 4.3) Commercial (1.4 to 1.6) Self-pay (1.1 to 1.4) Medicare (referent) *CI confidence interval; not applicable. Controlling for all variables listed as well as site and year of diagnosis, censored at date of death or at the end of the first year after diagnosis if still enrolled. Includes 16 patients with sex coded as other in the health maintenance organizations electronic cancer registry files. Prognosis was based on 5-year mortality rates for each type of cancer. provide the data needed to directly contact the individuals for follow-up studies. Among the strengths of this study is the large size of the population, which enabled us to produce precise estimates of retention rates among subgroups of age and race/ethnicity, cancer type, and insurance type. The availability of complete cancer registries linked to HMO enrollment files ensured that we could thoroughly ascertain cancer diagnoses among enrollees. However, although the cancer registries of these five CRN sites have accurate models for tracking mortality, there is a possibility that the deaths of some patients who had disenrolled from an HMO may not have been captured. If that were the case, our results would, in fact, overestimate survival and, thus, underestimate the retention rate among survivors. Three major sources of cancer data in the United States SEER, the National Cancer Data Base, and the Centers for Disease Control and Prevention s National Program of Cancer Registries have been used for large-scale studies of cancer treatment. However, each source lacks information on some aspects of cancer care and excludes subgroups of the population. SEER registries collect data on treatment during the initial course of treatment (7) but do not include information on comorbidities (8). With linkage to claims data from the Medicare system, SEER s database expands to include ongoing treatment and follow-up care beyond the initial treatment period for patients aged 65 years or older. However, even with this expanded database, SEER registries do not have information on prescription drugs or access to patient records and exclude those patients who are enrolled in managed care. The National Cancer Data Base captures patients of all ages (9 11). However, this database is hospitalbased and is less able to capture information from ambulatory care settings, where cancer care is increasingly provided. The Centers for Disease Control and Prevention s National Program of Cancer Registries includes broad age and geographic ranges for cancer patients but is focused only on the initial course of treatment (12 14). The CRN is, therefore, able to fill some of the information gaps in these data sources. In conclusion, our finding of high enrollee retention rates in this cohort of HMO-enrolled patients during up to 5-years of follow-up suggests that valuable population laboratories can be built from the CRN information source and that it can serve as a base for studies of quality of care, survivorship, and longterm outcomes. REFERENCES (1) Hewitt M, Simone JV, editors. Ensuring quality cancer care. Washington (DC): National Academy Press; p. 2. (2) Hewitt M, Simone JV. Enhancing data systems to improve the quality of care. Washington (DC): National Academy Press; (3) Stewart SL, Swallen KC, Glaser SL, Horn- Ross PL, West DW. Comparison of methods for classifying Hispanic ethnicity in a population-based cancer registry. Am J Epidemiol 1999;149: (4) StatCorp. Stata Statistical Software (release 6.0). College Station (TX): Stata Corporation; Journal of the National Cancer Institute, Vol. 96, No. 2, January 21, 2004 BRIEF COMMUNICATIONS 151
5 (5) Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982;69: (6) Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81: (7) Hankey BF, Ries LA, Edwards BK. The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev 1999;8: (8) Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER- Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002;40: IV-3 IV-18. (9) Stewart AK, Bland KI, McGinnis LS Jr, Morrow M, Eyre HG. Clinical highlights from the National Cancer Data Base, CA Cancer J Clin 2000;50: (10) American College of Surgeons National Cancer Data Base (NCDB) What is the NCDB? (Available at: cancer/ncdb/ncdbabout.html). Last accessed December 5, (11) Menck HR, Cunningham MP, Jessup JM, Eyre HJ, Winchester DP, Scott-Conner CE, et al. The growth and maturation of the National Cancer Data Base. Cancer 1997;80: (12) DHHS. Centers for Disease Control and Prevention (CDC) The National Program of Cancer Registries 2003 Program Fact Sheet Cancer Registries: The Foundation for Cancer Prevention and Control. Available at: htm. (Last accessed December 8, 2003.) (13) Bickell NA, Chassin MR. Determining the quality of breast cancer care: do tumor registries measure up? Ann Intern Med 2000; 132: (14) Malin JL, Kahn KL, Adams J, Kwan L, Laouri M, Ganz PA. Validity of cancer registry data for measuring the quality of breast cancer care. J Natl Cancer Inst 2002; 94: NOTES 1 Editor s note: SEER is a set of geographically defined, population-based central cancer registries in the United States, operated by nonprofit organizations under contract to the National Cancer Institute (NCI). Registry data are submitted electronically without personal identifiers to the NCI on a biannual basis, and the NCI makes the data available to the public for scientific research. This study was carried out under the auspices of the Cancer Research Network and was supported by Public Health Service grant CA79689 and an administrative supplement from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services. Manuscript received May 8, 2003; revised October 27, 2003; accepted November 3, BRIEF COMMUNICATIONS Journal of the National Cancer Institute, Vol. 96, No. 2, January 21, 2004
Body Mass Index Measurement and Obesity Prevalence in Ten U.S. Health Plans
CM&R Rapid Release. Published online ahead of print August 3, 2010 as Original Research Body Mass Index Measurement and Obesity Prevalence in Ten U.S. Health Plans David E. Arterburn, MD, MPH; Gwen L.
More informationSTUDY. The Association of Medicare Health Care Delivery Systems With Stage at Diagnosis and Survival for Patients With Melanoma
STUDY The Association of Medicare Health Care Delivery Systems With Stage at Diagnosis and Survival for Patients With Melanoma Robert S. Kirsner, MD, PhD; James D. Wilkinson, MD, MPH; Fangchao Ma, MD,
More informationFinal Report 22 January 2014
Final Report 22 January 2014 Cohort Study of Pioglitazone and Cancer Incidence in Patients with Diabetes Mellitus, Follow-up 1997-2012 Kaiser Permanente Division of Research Assiamira Ferrara, MD, Ph.D.
More informationThe Linked SEER-Medicare Data and Cancer Effectiveness Research
The Linked SEER-Medicare Data and Cancer Effectiveness Research Arnold L. Potosky, PhD Professor of Oncology Director of Health Services Research Georgetown University Medical Center Lombardi Comprehensive
More informationSurvival among Native American Adolescent and Young Adult Cancer Patients in California
Survival among Native American Adolescent and Young Adult Cancer Patients in California Cyllene R. Morris, 1 Yi W. Chen, 1 Arti Parikh-Patel, 1 Kenneth W. Kizer, 1 Theresa H. Keegan 2 1 California Cancer
More informationIndian Health Service Care System and Cancer Stage in American Indians and Alaska Natives
Indian Health Service Care System and Cancer Stage in American Indians and Alaska Natives Andrea N. Burnett-Hartman, Scott V. Adams, Aasthaa Bansal, Jean A. McDougall, Stacey A. Cohen, Andrew Karnopp,
More informationAnnual Report to the Nation on the Status of Cancer, , Featuring Survival Questions and Answers
EMBARGOED FOR RELEASE CONTACT: Friday, March 31, 2017 NCI Media Relations Branch: (301) 496-6641 or 10:00 am EDT ncipressofficers@mail.nih.gov NAACCR: (217) 698-0800 or bkohler@naaccr.org ACS Press Office:
More informationAdjuvant Chemotherapy for Patients with Stage III Colon Cancer: Results from a CDC-NPCR Patterns of Care Study
COLON CANCER ORIGINAL RESEARCH Adjuvant Chemotherapy for Patients with Stage III Colon Cancer: Results from a CDC-NPCR Patterns of Care Study Rosemary D. Cress 1, Susan A. Sabatino 2, Xiao-Cheng Wu 3,
More informationSpending estimates from Cancer Care Spending
CALIFORNIA HEALTHCARE FOUNDATION August 2015 Estimating Cancer Care Spending in the California Medicare Population: Methodology Detail This paper describes in detail the methods used by Deborah Schrag,
More informationAn Overview of Survival Statistics in SEER*Stat
An Overview of Survival Statistics in SEER*Stat National Cancer Institute SEER Program SEER s mission is to provide information on cancer statistics in an effort to reduce the burden of cancer among the
More informationNational Cancer Institute
Patient- reported outcome surveillance in older cancer survivors: Using the SEER-MHOS linked data resource Erin E. Kent, PhD Epidemiologist & Program Director Outcomes Research Branch Applied Research
More informationAndrogen deprivation therapy for treatment of localized prostate cancer and risk of
Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies Lauren P. Wallner, Renyi Wang, Steven J. Jacobsen, Reina Haque Department of Research and
More informationTHE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA
THE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA Presented by: Bryan Rettig, MS Nebraska Dept. of Health & Human Services Division of Public Health May 31, 2017 Nebraska Cancer Registry
More information6/20/2012. Co-authors. Background. Sociodemographic Predictors of Non-Receipt of Guidelines-Concordant Chemotherapy. Age 70 Years
Sociodemographic Predictors of Non-Receipt of Guidelines-Concordant Chemotherapy - among Locoregional Breast Cancer Patients Under Age 70 Years Xiao-Cheng Wu, MD, MPH 2012 NAACCR Annual Conference June
More informationThe first year counts: cancer survival among Indigenous and non-indigenous Queenslanders
The first year counts: cancer survival among Indigenous and non-indigenous Queenslanders 1997-2006 Author Cramb, Susanna M., Garvey, Gail, Valery, Patricia C., Williamson, John D., Baade, Peter D. Published
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION A Population-Based Study of Bilateral Efficacy in Women at Elevated Risk for Breast Cancer in Community Practices Ann M. Geiger, PhD; Onchee Yu, MS; Lisa J. Herrinton, PhD; William
More informationGSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationUsing claims data to investigate RT use at the end of life. B. Ashleigh Guadagnolo, MD, MPH Associate Professor M.D. Anderson Cancer Center
Using claims data to investigate RT use at the end of life B. Ashleigh Guadagnolo, MD, MPH Associate Professor M.D. Anderson Cancer Center Background 25% of Medicare budget spent on the last year of life.
More informationEpidemiology in Texas 2006 Annual Report. Cancer
Epidemiology in Texas 2006 Annual Report Cancer Epidemiology in Texas 2006 Annual Report Page 94 Cancer Incidence and Mortality in Texas, 2000-2004 The Texas Department of State Health Services Texas Cancer
More informationEstimated Minnesota Cancer Prevalence, January 1, MCSS Epidemiology Report 04:2. April 2004
MCSS Epidemiology Report 04:2 Suggested citation Perkins C, Bushhouse S.. Minnesota Cancer Surveillance System. Minneapolis, MN, http://www.health.state.mn.us/divs/hpcd/ cdee/mcss),. 1 Background Cancer
More informationIncidence cost estimates or longitudinal estimates of medical
CONDUCTING THE COST ANALYSIS Comparison of Approaches for Estimating Incidence Costs of Care for Colorectal Cancer Patients K. Robin Yabroff, PhD,* Joan L. Warren, PhD,* Deborah Schrag, MD, Angela Mariotto,
More informationAmerican Cancer Society Progress Report. December 2016
American Cancer Society Progress Report December 2016 2015 Goals Incidence: By 2015, 25% reduction (unlikely to meet goal) Baseline 1992-2013: 12.1% reduction Latest joinpoint trend: -1.5% APC (2009-2013)
More informationCERCIT Workshop: Texas Cancer Registry; Medicaid; Registry Linked Claims Data
CERCIT Workshop: About the Data: Texas Cancer Registry; Medicaid; Registry Linked Claims Data MelanieWilliams,PhD,Manager, Texas Cancer Registry Melanie Williams, PhD, Manager, Texas Cancer Registry Cheryl
More informationThe Cancer Burden in California. Janet Bates MD MPH California Cancer Registry California Department of Public Health April 25, 2012
The Cancer Burden in California Janet Bates MD MPH California Cancer Registry California Department of Public Health April 25, 2012 Goals Introduce you to the California Cancer Registry (CCR) Provide an
More informationResearch Article Recognition of Depression and Anxiety among Elderly Colorectal Cancer Patients
Nursing Research and Practice Volume 2010, Article ID 693961, 8 pages doi:10.1155/2010/693961 Research Article Recognition of Depression and Anxiety among Elderly Colorectal Cancer Patients Amy Y. Zhang
More informationAbstract Objective: To examine whether general preventive services were diminished in a cohort of men after their diagnosis of prostate cancer.
Original Article Quality of Preventive Care Before and After Prostate Cancer Diagnosis Lauren Wallner, PhD, MPH; Jeff M. Slezak, MS; Virginia P. Quinn, PhD, MPH; Ronald K. Loo, MD; Joanne E. Schottinger,
More informationRacial Variation In Quality Of Care Among Medicare+Choice Enrollees
Racial Variation In Quality Of Care Among Medicare+Choice Enrollees Black/white patterns of racial disparities in health care do not necessarily apply to Asians, Hispanics, and Native Americans. by Beth
More informationHypertension and diabetes treatments and risk of adverse outcomes among breast cancer patients. Lu Chen
Hypertension and diabetes treatments and risk of adverse outcomes among breast cancer patients Lu Chen A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy
More informationWill Equity Be Achieved Through Health Care Reform?
Will Equity Be Achieved Through Health Care Reform? John Z. Ayanian, MD, MPP Director & Alice Hamilton Professor of Medicine Mass Medical Society Public Health Leadership Forum April 4, 214 OBJECTIVES
More informationThe projection of short- and long-term survival for. Conditional Survival Among Patients With Carcinoma of the Lung*
Conditional Survival Among Patients With Carcinoma of the Lung* Ray M. Merrill, PhD, MPH; Donald Earl Henson, MD; and Michael Barnes, PhD Objective: One- and 5-year probabilities of survival or death change
More informationCancer Prevention Institute of California, Fremont, California. 2. Stanford Cancer Institute, Stanford, California. 3
How much of the racial/ethnic disparities in cancer survival in California is explained by differences in tumor, sociodemographic, institutional and neighborhood characteristics? Elizabeth Ellis 1,2, Alison
More informationChapter 2: Identification and Care of Patients With CKD
Chapter 2: Identification and Care of Patients With CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More informationFinancial Hardship in Cancer Survivors
Financial Hardship in Cancer Survivors Robin Yabroff Robin.yabroff@hhs.gov The views expressed are those of the speaker and do not necessarily represent the official position of Department of Health and
More informationDiagnosis and Treatment of Neuropathy Post Chemotherapy in Three Health Care Systems
Diagnosis and Treatment of Neuropathy Post Chemotherapy in Three Health Care Systems HCSRN 2019 Conference April 10, 2019 Kaiser Permanente Research Peripheral neuropathy is a common side effect of neurotoxic
More informationLinkage of Indiana State Cancer Registry and Indiana Network for Patient Care
Linkage of Indiana State Cancer Registry and Indiana Network for Patient Care A collaboration between Regenstrief Institute, Indiana University, and the Indiana State Cancer Registry Objectives Understand
More informationCCSS Concept Proposal Working Group: Biostatistics and Epidemiology
Draft date: June 26, 2010 CCSS Concept Proposal Working Group: Biostatistics and Epidemiology Title: Conditional Survival in Pediatric Malignancies: A Comparison of CCSS and SEER Data Proposed Investigators:
More informationTable of Contents. 2 P age. Susan G. Komen
RHODE ISLAND Table of Contents Table of Contents... 2 Introduction... 3 About... 3 Susan G. Komen Affiliate Network... 3 Purpose of the State Community Profile Report... 4 Quantitative Data: Measuring
More informationWHAT FACTORS INFLUENCE AN ANALYSIS OF HOSPITALIZATIONS AMONG DYING CANCER PATIENTS? AGGRESSIVE END-OF-LIFE CANCER CARE. Deesha Patel May 11, 2011
WHAT FACTORS INFLUENCE HOSPITALIZATIONS AMONG DYING CANCER PATIENTS? AN ANALYSIS OF AGGRESSIVE END-OF-LIFE CANCER CARE. Deesha Patel May 11, 2011 WHAT IS AGGRESSIVE EOL CARE? Use of ineffective medical
More informationInsurance Providers Reduce Diabetes Risk Through CDC Program
Insurance Providers Reduce Diabetes Risk Through CDC Program ISSUE BRIEF JULY 2018 KEY TAKEAWAYS 86 million Americans 1 in 3 adults have pre-diabetes. Studies show that losing 5 to 7 percent of body weight
More informationNIH Public Access Author Manuscript Cancer. Author manuscript; available in PMC 2006 December 17.
NIH Public Access Author Manuscript Published in final edited form as: Cancer. 2005 December 15; 104(12 Suppl): 2989 2998. 1999 2001 Cancer Mortality Rates for Asian and Pacific Islander Ethnic Groups
More informationOCTOBER 2011 MEDICAID AND HIV: A NATIONAL ANALYSIS
OCTOBER 2011 MEDICAID AND HIV: A NATIONAL ANALYSIS MEDICAID AND HIV: A NATIONAL ANALYSIS OCTOBER 2011 Prepared by JEN KATES EXECUTIVE SUMMARY Medicaid, the nation s principal safety-net health insurance
More informationHEALTH CARE EXPENDITURES ASSOCIATED WITH PERSISTENT EMERGENCY DEPARTMENT USE: A MULTI-STATE ANALYSIS OF MEDICAID BENEFICIARIES
HEALTH CARE EXPENDITURES ASSOCIATED WITH PERSISTENT EMERGENCY DEPARTMENT USE: A MULTI-STATE ANALYSIS OF MEDICAID BENEFICIARIES Presented by Parul Agarwal, PhD MPH 1,2 Thomas K Bias, PhD 3 Usha Sambamoorthi,
More informationChapter 2: Identification and Care of Patients with CKD
Chapter 2: Identification and Care of Patients with CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More informationTraining, Quality Assurance, and Assessment of Medical Record Abstraction in a Multisite Study
American Journal of Epidemiology Copyright 2003 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 157, No. 6 Printed in U.S.A. DOI: 10.1093/aje/kwg016 Training, Quality Assurance,
More informationThe University of Mississippi School of Pharmacy
LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.
More informationHealthcare Reform and Cancer Survivorship: Implications for Care & Research
Healthcare Reform and Cancer Survivorship: Implications for Care & Research Julia H. Rowland, Ph.D., Director Office of Cancer Survivorship National Cancer Institute National Institutes of Health DHHS
More informationStatus of the CKD and ESRD treatment: Growth, Care, Disparities
Status of the CKD and ESRD treatment: Growth, Care, Disparities United States Renal Data System Coordinating Center An J. Collins, MD FACP Director USRDS Coordinating Center Robert Foley, MB Co-investigator
More informationIncidence of Primary Liver Cancer in American Indians and Alaska Natives
Incidence of Primary Liver Cancer in American Indians and Alaska Natives Stephanie C. Melkonian, PhD Epidemiologist Epidemiology and Applied Research Branch NAACCR Annual Conference June 21, 2017 Overview
More informationThe American Cancer Society estimates that there will be
ORIGINAL ARTICLE Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,* David M. Kent, MD, MS, and Gary M.
More informationCANCER FACTS & FIGURES For African Americans
CANCER FACTS & FIGURES For African Americans Pennsylvania, 2006 Pennsylvania Cancer Registry Bureau of Health Statistics and Research Contents Data Hightlights...1 Pennsylvania and U.S. Comparison...5
More informationInsights from the Kaiser Permanente database
Insights from the Kaiser Permanente database Jashin J. Wu, M.D. Founding Director of Dermatology Research Director, Psoriasis Clinic Department of Dermatology Kaiser Permanente Los Angeles Medical Center
More informationChapter 2: Identification and Care of Patients With CKD
Chapter 2: Identification and Care of Patients With Over half of patients from the Medicare 5% sample (restricted to age 65 and older) have a diagnosis of chronic kidney disease (), cardiovascular disease,
More informationWellness Coaching for People with Prediabetes
Wellness Coaching for People with Prediabetes PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY Volume 12, E207 NOVEMBER 2015 ORIGINAL RESEARCH Wellness Coaching for People With Prediabetes: A Randomized Encouragement
More informationKey Words. SEER Cancer Survival Incidence Mortality Prevalence
The Oncologist Cancer Survival and Incidence from the Surveillance, Epidemiology, and End Results (SEER) Program LYNN A. GLOECKLER RIES, MARSHA E. REICHMAN, DENISE RIEDEL LEWIS, BENJAMIN F. HANKEY, BRENDA
More informationNIH Public Access Author Manuscript Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2011 January 1.
NIH Public Access Author Manuscript Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2010 January ; 19(1): 144 147. doi:10.1158/1055-9965.epi-09-0807. Feasibility Study for Collection
More informationPRINCIPLES FOR ELIMINATING DISPARITIES THROUGH HEALTH CARE REFORM. John Z. Ayanian, MD, MPP
PRINCIPLES FOR ELIMINATING DISPARITIES THROUGH HEALTH CARE REFORM John Z. Ayanian, MD, MPP Harvard Medical School Brigham and Women s Hospital Harvard School of Public Health 8 th Annual National Summit
More informationOVER the past three decades, numerous randomized
Journal of Gerontology: MEDICAL SCIENCES 2005, Vol. 60A, No. 9, 1137 1144 Copyright 2005 by The Gerontological Society of America Effectiveness of Adjuvant for Node-Positive Operable Breast Cancer in Older
More informationIdentifying Geographic & Socioeconomic Disparities in Access to Care for Pediatric Cancer Patients in Texas
Identifying Geographic & Socioeconomic Disparities in Access to Care for Pediatric Cancer Patients in Texas Mary T. Austin, MD, MPH Assistant Professor, Pediatric Surgery University of Texas Health Science
More informationCHRONIC HEPATITIS B AND C COHORT STUDY (CHECS)
CHRONIC HEPATITIS B AND C COHORT STUDY (CHECS) CDC CONTACT Scott D Holmberg, M.D., M.P.H. Chief, Epidemiology and Surveillance Branch Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis,
More informationA Methodological Issue in the Analysis of Second-Primary Cancer Incidence in Long-Term Survivors of Childhood Cancers
American Journal of Epidemiology Copyright 2003 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 158, No. 11 Printed in U.S.A. DOI: 10.1093/aje/kwg278 PRACTICE OF EPIDEMIOLOGY
More informationOverview from the Division of Cancer Prevention and Control
Overview from the Division of Cancer Prevention and Control Lisa C. Richardson, MD, MPH Director, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention (CDC) Advisory Committee
More informationCERCIT Project 2: Assessing the Quality of Cancer Treatment in Texas. Sharon Giordano
CERCIT Project 2: Assessing the Quality of Cancer Treatment in Texas Sharon Giordano October 21, 2011 Specific Aims Determine the agreement of the Texas Cancer Registry and claims databases for the rates
More informationCancer survival and prevalence in Tasmania
Cancer survival and prevalence in Tasmania 1978-2008 Cancer survival and prevalence in Tasmania 1978-2008 Tasmanian Cancer Registry University of Tasmania Menzies Research Institute Tasmania 17 Liverpool
More informationTable of Contents. 2 P a g e. Susan G. Komen
NEW HAMPSHIRE Table of Contents Table of Contents... 2 Introduction... 3 About... 3 Susan G. Komen Affiliate Network... 3 Purpose of the State Community Profile Report... 4 Quantitative Data: Measuring
More informationDepartment of Human Services/Oregon Health Authority Addictions and Mental Health Division (AMH) November 25, 2009
Disclaimer High Level Briefing on Addiction Treatment System Prepared for the Alcohol and Drug Policy Commission This paper reflects only the highest level briefing information about the addiction treatment
More informationGSK Medicine: Study No.: Title: Rationale: Objectives: Indication: Study Investigators/Centers: Research Methods:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPresentation for DHSS 14 September Senior Statistician
Presentation for DHSS 14 September 2014 Jeannette Jackson-Thompson, MSPH, PhD Director Chester Schmaltz, PhD Senior Statistician Missouri Cancer Registry and Research Center (MCR-ARC) University of Missouri
More informationThe Current Landscape of Nurse Navigators: Oncology and the Impact on Outcomes
The Current Landscape of Nurse Navigators: Oncology and the Impact on Outcomes SHERYL RILEY RN, OCN, CMCN DIRECTOR OF CLINICAL SERVICES SAI SYSTEMS SRILEY@SAISYSTEMS.COM 2015 SAI SYSTEMS INTERNATIONAL
More informationExamining Racial Differences in Utilization of Genetic Counseling Services in Hereditary Cancer Network Database
Examining Racial Differences in Utilization of Genetic Counseling Services in Hereditary Cancer Network Database Taylor Seaton, MS Cancer Genomics Epidemiologist MDHHS Cancer Genomics Program: Lifecourse
More informationORIGINAL INVESTIGATION. Effect of a Dementia Diagnosis on Survival of Older Patients After a Diagnosis of Breast, Colon, or Prostate Cancer
ORIGINAL INVESTIGATION Effect of a Dementia Diagnosis on Survival of Older Patients After a Diagnosis of Breast, Colon, or Prostate Cancer Implications for Cancer Care Mukaila A. Raji, MD, MSc; Yong-Fang
More informationPCORnet Use Cases. Observational study: Dabigatran vs warfarin and ischemic and hemorrhagic stroke / extra-cranial bleeding
PCORnet Use Cases Observational study: Dabigatran vs warfarin and ischemic and hemorrhagic stroke / extra-cranial bleeding 1 Observational study: Dabigatran vs warfarin and stroke / bleeding Goal: Compare
More informationKey Words. Cancer statistics Incidence Lifetime risk Multiple primaries Survival SEER
The Oncologist Epidemiology and Population Studies: SEER Series Cancer Statistics, Trends, and Multiple Primary Cancer Analyses from the Surveillance, Epidemiology, and End Results (SEER) Program MATTHEW
More informationConstruction of a North American Cancer Survival Index to Measure Progress of Cancer Control Efforts
Construction of a North American Cancer Survival Index to Measure Progress of Cancer Control Efforts Chris Johnson, Cancer Data Registry of Idaho NAACCR 2016 Annual Conference June 14, 2016 Concurrent
More informationAnnual Report to the Nation on the Status of Cancer, , Featuring Survival
JNCI J Natl Cancer Inst (217) 19(9): djx3 doi: 1.193/jnci/djx3 First published online March 31, 217 Article Annual Report to the Nation on the Status of Cancer, 1975 214, Featuring Survival Ahmedin Jemal,
More informationTable of Contents. 2 P age. Susan G. Komen
OREGON Table of Contents Table of Contents... 2 Introduction... 3 About... 3 Susan G. Komen Affiliate Network... 3 Purpose of the State Community Profile Report... 4 Quantitative Data: Measuring Breast
More informationTHE IMPORTANCE OF COMORBIDITY TO CANCER CARE AND STATISTICS AMERICAN CANCER SOCIETY PRESENTATION COPYRIGHT NOTICE
THE IMPORTANCE OF COMORBIDITY TO CANCER CARE AND STATISTICS AMERICAN CANCER SOCIETY PRESENTATION COPYRIGHT NOTICE Washington University grants permission to use and reproduce the The Importance of Comorbidity
More informationCANCER IS A COMMON CAUSE
ORIGINAL CONTRIBUTION Hospice Use Among Medicare Managed Care and Fee-for-Service Dying With Cancer Ellen P. McCarthy, PhD, MPH Risa B. Burns, MD, MPH Quyen Ngo-Metzger, MD, MPH Roger B. Davis, ScD Russell
More informationComparative Effectiveness Research in Cancer: Robert T. Croyle, Ph.D. y, National Cancer Institute October 2010
Comparative Effectiveness Research in Cancer: Past, Present and Future Robert T. Croyle, Ph.D. y, National Cancer Institute October 2010 Presentation Overview Past Clinical trials system and population
More informationIncidence of Surgically Treated Benign Prostatic Hypertrophy and of Prostate Cancer among Blacks and Whites in a Prepaid Health Care Plan
American Journal of EpKtermotogy Vo! 134, No 8 Copyright C 1991 by The Johns Hopkrts Uruversfty School of Hygiene and Put*: Health Printed in US A AS rights reserved A BRIEF ORIGINAL CONTRIBUTION Incidence
More informationDuring the past 2 decades, an increase in the ageadjusted
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:104 110 Racial Differences in Survival of Hepatocellular Carcinoma in the United States: A Population-Based Study JESSICA A. DAVILA* and HASHEM B. EL SERAG*,
More informationpreventive health care measure
introduction 98 < pre- & post-esrd preventive care 1 < diabetic care 12 < cancer screening 14 < chapter summary 16 Chapter Five preventive health care measure SSo neither ought you to attempt to cure the
More informationCancer Facts & Figures for African Americans
Cancer Facts & Figures for African Americans What is the Impact of Cancer on African Americans in Indiana? Table 12. Burden of Cancer among African Americans Indiana, 2004 2008 Average number of cases
More informationInsurance Coverage Changes for People with HIV Under the ACA
Insurance Coverage Changes for People with HIV Under the ACA Jennifer Kates, Lindsey Dawson Prior to the Affordable Care Act (ACA), people with HIV faced limited access to insurance coverage due to several
More informationCancer in Rural Illinois, Incidence, Mortality, Staging, and Access to Care. April 2014
Cancer in Rural Illinois, 1990-2010 Incidence, Mortality, Staging, and Access to Care April 2014 Prepared by Whitney E. Zahnd, MS Research Development Coordinator Center for Clinical Research Southern
More informationComparison of Self-reported Fecal Occult Blood Testing with Automated Laboratory Records among Older Women in a Health Maintenance Organization
American Journal of Epidemiology Copyright 01999 by The Johns Hopkins University School of Hygiene and Public Health All rights reserved Vol.150,. 6 Printed In USA. Comparison of Self-reported Fecal Occult
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationCancer Disparities in Arkansas: An Uneven Distribution. Prepared by: Martha M. Phillips, PhD, MPH, MBA. For the Arkansas Cancer Coalition
Cancer Disparities in Arkansas: An Uneven Distribution Prepared by: Martha M. Phillips, PhD, MPH, MBA For the Arkansas Cancer Coalition Table of Contents Page Burden of Cancer 3 Cancer Disparities 3 Cost
More informationmedicaid and the The Role of Medicaid for People with Diabetes
on medicaid and the uninsured The Role of for People with Diabetes November 2012 Introduction Diabetes is one of the most prevalent chronic conditions and a leading cause of death in the United States.
More informationState of Alabama AIDS Drug Assistance Program (ADAP) Quarterly Report
State of Alabama AIDS Drug Assistance Program (ADAP) Quarterly Report This report reflects active clients currently enrolled in ADAP Full-pay Prescription Program (ADAP-Rx), Alabama s Insurance Assistance
More informationOverview of Gynecologic Cancers in New Jersey
Overview of Gynecologic Cancers in New Jersey New Jersey State Cancer Registry Antoinette M. Stroup, PhD presented at: Gynecologic Cancer Symposium: Striving for a Healthier Tomorrow, Today November 19,
More informationTexas Chronic Disease Burden Report. April Publication #E
Texas Chronic Disease Burden Report April 2010 Publication #E81-11194 Direction and Support Lauri Kalanges, MD, MPH Medical Director Health Promotion and Chronic Disease Prevention Section, Texas Department
More informationTools, Reports, and Resources
Tools, Reports, and Resources What the National Cancer Database (NCDB) does for CoC-Accredited Programs By using the NCDB, CoC-accredited programs can proactively improve delivery and quality of care for
More informationBreast cancer, diagnosed in 180,000 women in the United
Delayed Radiotherapy for Breast Cancer Patients in Integrated Delivery Systems Heather Taffet Gold, PhD; Soe Soe Thwin, PhD; Diana S. M. Buist, PhD, MPH; Terry S. Field, DSc; Feifei Wei, PhD; Marianne
More informationAuthors: Shuling Li, PhD 1, Julia Molony, MS 1, Karynsa Cetin, MPH 2, Jeffrey Wasser, MD 3, Ivy Altomare, MD 4
Rate of Bleeding-Related Episodes (BREs) in Elderly Patients with Primary Immune Thrombocytopenia (ITP): A Population-Based Retrospective Cohort Study Using Medicare 20% Sample Data Authors: Shuling Li,
More informationAssessing the Comparability of EMR Information to Patient Registry and Health Claims Data
Assessing the Comparability of EMR Information to Patient Registry and Health Claims Data F.S. Mowat, 1 E.C. Lau, 1 M.A. Kelsh, 2* J.C. Legg, 2 N.M. Engel-Nitz, 3 H.N. Watson, 1 H.L. Collins, 2 R.J. Nordyke,
More informationImpact of Florida s Medicaid Reform on Recipients of Mental Health Services
Impact of Florida s Medicaid Reform on Recipients of Mental Health Services Jeffrey Harman, PhD John Robst, PhD Lilliana Bell, MHA The Quality of Behavioral Healthcare : A Drive for Change Through Research
More informationEmerging Issues in Cancer Prevention and Control
Emerging Issues in Cancer Prevention and Control Marcus Plescia, MD, MPH Director, Division of Cancer Prevention and Control Centers for Disease Control & Prevention National Center for Chronic Disease
More informationRacial and ethnic disparities in diabetes risk after gestational diabetes mellitus
Diabetologia (2011) 54:3016 3021 DOI 10.1007/s00125-011-2330-2 ARTICLE Racial and ethnic disparities in diabetes risk after gestational diabetes mellitus A. H. Xiang & B. H. Li & M. H. Black & D. A. Sacks
More informationMultnomah County: Leading Causes of Death
Leading causes of death are presented in this report by gender and race/ethnicity. Mortality data is based on the Death Certificate statistical file provided by the Center for Health Statistics, Oregon
More informationBLACK-WHITE DIFFERENCES IN SURVIVAL FROM LATE-STAGE PROSTATE CANCER
BLACK-WHITE DIFFERENCES IN SURVIVAL FROM LATE-STAGE PROSTATE CANCER Objective: To examine differences between African Americans (Blacks) and non-hispanic Whites in risk of death after diagnosis of laterstage
More information